乙型肝炎病毒的S基因突变和抗HBs亚型非特异性导致HBsAg和抗HB

StephenW

J Med Virol. 2017 Feb 15. doi: 10.1002/jmv.24782. [Epub ahead of print]
Mutation in the S gene of hepatitis B virus and anti-HBs subtype-nonspecificity contributed to the coexistence of HBsAg and anti-HBs in patients with chronic hepatitis B virus infection.Fu X1,2,3, Chen J1,3, Chen H1,3, Lin J1,3, Xun Z1,2,3, Li S1,2,3, Liu C1,3, Zeng Y1,3, Chen T1,3, Yang B1,3, Ou Q1,3.
Author information

• 1Department of Laboratory Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
• 2First Clinical College, Fujian Medical University, Fuzhou, China.
• 3The Genetic Diagonstic Laboratory, The First Affiliated Hospital of Fujian Medical University, China.
  

AbstractThe mechanism for the coexistence of hepatitis B surface antigen (HBsAg) and antibodies to HBsAg (anti-HBs) in chronic HBV infected patients remains controversial. This study aimed to explore the role of HBV S gene mutation and anti-HBs subtype-nonspecificity in patients with simultaneous HBsAg/anti-HBs positivity. Chronic HBV infections with (n = 145, group I) and without (n = 141, group II) anti-HBs were included. The S gene was amplified and sequenced. The neutralization experiment was used in group I patients' sera to determine the specificity of anti-HBs. Additionally, the HBV vaccinated persons' sera were used to estimate the neutralize capacity of anti-HBs against HBsAg in group I patients. Results showed that 2.63% (145/5513) chronic HBV infected patients had positive results for anti-HBs. HBsAg amino acid (aa) substitution rate in 35 patients of group I was significantly higher than that in 58 patients of group II (1.89% vs. 0.95%, P < 0.05), especially within 'a' determinant (4.05% vs. 1.22%, P < 0.05). In group I patients, anti-HBs in (74.29%, 26/35) patients was not directed to the subtypes of the co-existing HBsAg. Besides, some HBsAg variations in group I patients, sG145R mutation, inserted mutations and continuous aa mutations within the major hydrophilic region (MHR), decreased the neutralized capacity of anti-HBs from HBV vaccinated persons. In conclusion, both of HBsAg mutation and anti-HBs subtype-nonspecificity contributed to the coexistence of HBsAg and anti-HBs in chronic HBV infection. HBV vaccine recipients may still have a risk of HBV infection when exposure to patients with simultaneous HBsAg/anti-HBs positivity. This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.

KEYWORDS: antibodies to HBsAg; coexistence; hepatitis B surface antigen; mutation; serotype

PMID:28198078DOI:10.1002/jmv.24782

StephenW

J Med Virol。 2017年2月15日。doi：10.1002 / jmv.24782。 [印刷前电子版]
乙型肝炎病毒的S基因突变和抗HBs亚型非特异性导致HBsAg和抗HBs在慢性乙型肝炎病毒感染患者中的共存。
Fu X1,2,3，Chen J1,3，Chen H1,3，Lin J1,3，Xun Z1,2,3，Li S1,2,3，Liu C1,3，Zeng Y1,3，Chen T1,3 ，Yang B1,3，Ou Q1,3。
作者信息

    福建医科大学附属第一医院实验医学科。
    2福建医科大学第一临床学院，福州。
    福建医科大学第一附属医院遗传诊断实验室，中国。

抽象

在慢性HBV感染患者中乙型肝炎表面抗原（HBsAg）和HBsAg抗体（抗HBs）共存的机制仍有争议。本研究旨在探讨HBV S基因突变和抗HBs亚型非特异性在同时HBsAg /抗HBs阳性患者中的作用。包括（n = 145，I组）和无（n = 141，II组）抗HB的慢性HBV感染。扩增S基因并测序。中和实验用于I组患者的血清以确定抗HBs的特异性。此外，HBV免疫人血清用于评估抗HBs对I组患者中HBsAg的中和能力。结果显示，2.63％（145/5513）慢性HBV感染患者的抗HBs阳性结果。第一组35例患者的HBsAg氨基酸（aa）替代率显着高于第二组58例患者（1.89％vs. 0.95％，P <0.05），尤其是在“a”决定因素（4.05％vs. 1.22 ％，P <0.05）。在I组患者中，（74.29％，26/35）患者中的抗HBs不针对共存的HBsAg的亚型。此外，第一组患者的一些HBsAg变异，sG145R突变，主要亲水区（MHR）内的插入突变和连续aa突变降低了来自HBV接种人的抗HBs的中和能力。总之，HBsAg突变和抗HBs亚型非特异性有助于HBsAg和抗HBs在慢性HBV感染的共存。 HBV疫苗接种者在暴露于同时HBsAg /抗HBs阳性的患者时仍然具有HBV感染的风险。本文受版权保护。版权所有。

本文受版权保护。版权所有。
关键词：

抗HBsAg抗体;共存乙型肝炎表面抗原;突变;血清型

PMID：
    28198078
DOI：
    10.1002 / jmv.24782